[Expression and Clinical Significance of LncRNA HEIH in Patients with Acute Myeloid Leukemia].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2024-08-01 DOI:10.19746/j.cnki.issn.1009-2137.2024.04.006

Yue Ma, Jia-Jia Li

{"title":"[Expression and Clinical Significance of LncRNA HEIH in Patients with Acute Myeloid Leukemia].","authors":"Yue Ma, Jia-Jia Li","doi":"10.19746/j.cnki.issn.1009-2137.2024.04.006","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the expression and clinical significance of long noncoding RNA(lncRNA) HEIH in patients with acute myeloid leukemia (AML).Methods: 50 newly diagnosed AML patients (except M3) admitted to the First Affiliated Hospital of Bengbu Medical College from January 2019 to December 2020 were included in the study, with 30 patients with non-hematological malignancies as controls. The relative expression level of lncRNA HEIH in all patients were detected, the correlation of clinical characteristics, gene mutations, FAB classification, efficacy, prognosis and overall survival (OS) of AML patients with the expression level of lncRNA HEIH were analyzed.Results: The expression level of lncRNA HEIH in AML patients was significantly higher than that in patients with non-hematological malignancies (P <0.01). Moreover, AML patients with high white blood cell count (WBC), CEBPA and FLT3 mutations, poor efficacy, and poor prognosis often showed higher expression of lncRNA HEIH, and patients with high lncRNA HEIH expression showed a shorter overall survival (OS).Conclusion: lncRNA HEIH shows an unique molecular biological significance in AML patients, which may provide a new approach for diagnosis, monitoring and targeted therapy of AML.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"32 4","pages":"1011-1017"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the expression and clinical significance of long noncoding RNA(lncRNA) HEIH in patients with acute myeloid leukemia (AML).

Methods: 50 newly diagnosed AML patients (except M3) admitted to the First Affiliated Hospital of Bengbu Medical College from January 2019 to December 2020 were included in the study, with 30 patients with non-hematological malignancies as controls. The relative expression level of lncRNA HEIH in all patients were detected, the correlation of clinical characteristics, gene mutations, FAB classification, efficacy, prognosis and overall survival (OS) of AML patients with the expression level of lncRNA HEIH were analyzed.

Results: The expression level of lncRNA HEIH in AML patients was significantly higher than that in patients with non-hematological malignancies (P <0.01). Moreover, AML patients with high white blood cell count (WBC), CEBPA and FLT3 mutations, poor efficacy, and poor prognosis often showed higher expression of lncRNA HEIH, and patients with high lncRNA HEIH expression showed a shorter overall survival (OS).

Conclusion: lncRNA HEIH shows an unique molecular biological significance in AML patients, which may provide a new approach for diagnosis, monitoring and targeted therapy of AML.

查看原文本刊更多论文

[急性髓性白血病患者 LncRNA HEIH 的表达及临床意义]。

研究目的方法：以蚌埠医学院第一附属医院2019年1月至2020年12月收治的50例新诊断AML患者（M3除外）为研究对象，30例非血液恶性肿瘤患者为对照，探讨长非编码RNA（lncRNA）HEIH在急性髓系白血病（AML）患者中的表达及临床意义。检测所有患者中lncRNA HEIH的相对表达水平，分析AML患者的临床特征、基因突变、FAB分级、疗效、预后及总生存期（OS）与lncRNA HEIH表达水平的相关性：结果：lncRNA HEIH在AML患者中的表达水平明显高于非血液恶性肿瘤患者（P CEBPA和FLT3突变、疗效差、预后差的患者常有较高的lncRNA HEIH表达，lncRNA HEIH高表达的患者总生存期（OS）较短）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊